Nanostructured Lipid Carriers to Enhance the Bioavailability and Solubility of Ranolazine: Statistical Optimization and Pharmacological Evaluations

• Main Authors: Aziz Unnisa (Author), Ananda K. Chettupalli (Author), Reem S. Alazragi (Author), Walla Alelwani (Author), Azzah M. Bannunah (Author), Jameel Barnawi (Author), Padmanabha R. Amarachinta (Author), Suresh B. Jandrajupalli (Author), Badria A. Elamine (Author), Omkalthoum A. Mohamed (Author), Talib Hussain (Author)
• Format: Book
• Published: MDPI AG, 2023-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Chronic stable angina pectoris is the primary indication for ranolazine (RZ), an anti-anginal drug. The drug has an anti-ischemic action that is unaffected by either blood pressure or heart rate. Due to the first-pass effect, the drug has a reduced bioavailability of 35 to 50%. The study emphasized...